Severe Thyroid Eye Disease
Linsitinib for thyroid eye disease shows proptosis reduction, safety in phase 2b/3 trial
Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.
Solving the TED Puzzle: Answering Your Questions on Diagnosis to Decision-Making
This activity is supported by educational funding provided by Amgen.
Thyroid Eye Disease Mastery: Multidisciplinary Approaches to Diagnosis and Treatment
This activity is supported by educational funding provided by Amgen.
Thyroid Eye Disease: Improving Clinical Practice With Real-World Insights
This activity is supported by educational funding provided by Amgen.
Thyroid Eye Disease: Navigating Diagnosis and Treatment in the Real World - A Podcast Series
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comprehensive Thyroid Eye Disease Management: Beyond the Bulge
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Thyroid Eye Disease 360° Guidance: Surgical Procedures, Research Trends, and Case Challenges
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comanagement of Thyroid Eye Disease for the Ophthalmology and Optometry Provider
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comanagement of Thyroid Disorders for the Endocrinology Provider
This activity is supported by and educational grant from Horizon Therapeutics USA, Inc.
VIDEO: Check for mimics of thyroid eye disease
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Andrew G. Lee, MD, discusses neuro-ophthalmic mimics of thyroid eye disease.